Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share 2022: Global Trends, Key Players, Industry Analysis Report to 2028

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market size is expected to grow at an annual average CAGR of 5% during 2022-2028. Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder that causes paralysis (impairment of sensory function in the extremities). It is caused by inflammation of the nerve roots, peripheral nerves, and destruction of the fatty protective sheath (myelin) over the nerve. It slows down the transmission of nerve signals, destroying nerve fibers. It can be treated with corticosteroids or immunosuppressants, plasma exchange, and intravenous immunoglobulin therapy.

The following segmentation are covered in this report:

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Treatment Type

Intravenous immunoglobulin therapy

• Privigen
• Hizentra
• Gamunex-C
• Tegeline
• Others

Corticosteroids

Others

 Company Profile

• Argenx
• CSL Behring
• GeNeuro Pharmaceuticals
• Grifols/Kedrion Biopharma
• LFB
• MedDay Pharmaceuticals
• Momenta Pharmaceuticals
• Nihon Pharmaceutical
• OctaPharma
• Pfizer
• Shire/ Takeda
• Teijin Pharma
• UCB Biopharma

Scope of the report

The research study analyses the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent developments

• Market overview and growth analysis
• Import and export overview
• Volume analysis
• Current market trends and future outlook
• Market opportunistic and attractive investment segment

Geographic coverage

• North america market size and/or volume
• Latin america market size and/or volume
• Europe market size and/or volume
• Asia-pacific market size and/or volume
• Rest of the world market size and/or volume

Key Questions Answered by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Report

• What was the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market size in 2020 and 2021; what are the estimated growth trends and market forecast (2022-2028)
• What will be the CAGR of Market during the forecast period (2022-2028)?
• Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).
• Which manufacturer/vendor/players in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market was the market leader in 2022?
• Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.